Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Data: Yahoo Finance; Chart: Axios Visuals

Moderna's stock soared 9% on Monday following a new federal grant and the official start of a late-stage trial for the company's coronavirus vaccine.

The bottom line: Moderna now has received almost $1 billion in taxpayer funds to help develop a vaccine that is tied to the work of federal scientists, and the stock market reactions signal that investors think they'll reap a lot of the reward if the vaccine is proven to work.

By the numbers: Moderna, which has no FDA-approved drugs on the market, is now valued at $31 billion.

  • The massive stock rally has paid off for executives. Moderna CEO Stéphane Bancel has sold $9 million worth of stock in July alone.

Go deeper

Updated Dec 1, 2020 - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Health: Coronavirus may have been in U.S. in December 2019, study finds — Hospital crisis deepens as holiday season nears.
  2. Politics: Bipartisan group of senators unveil $908 billion COVID stimulus proposalFDA chief was called to West Wing to explain why agency hasn't moved faster on vaccine — The words that actually persuade people on the pandemic
  3. Vaccine: Moderna to file for FDA emergency use authorizationVaccinating rural America won't be easy — Being last in the vaccine queue is young people's next big COVID test.
  4. States: Cuomo orders emergency hospital protocols as New York's COVID capacity dwindles.
  5. World: European regulators to assess first COVID-19 vaccine by Dec. 29
  6. 🎧 Podcast: The state of play of the top vaccines.
Dave Lawler, author of World
Nov 4, 2020 - World

Italy imposes regional lockdown as coronavirus cases spike

Prime Minister Giuseppe Conte (c) made the call. Photo: Antonio Masiello/Getty Images

Much of Italy will be placed under a strict lockdown as of Friday in the most drastic steps the country has taken to fight the coronavirus since it led the world into lockdown nearly eight months ago.

The big picture: Italy managed to keep the spread of the virus largely under control for months after a brutal first wave. But like much of Europe, it's currently recording unprecedented daily case counts and scrambling to avoid a return to overcrowded hospitals and climbing death tolls in the coming weeks.

Bryan Walsh, author of Future
Nov 4, 2020 - Health

Air pollution connected to higher COVID-19 death rates

Smokestacks in Florida. Photo: Getty Images

A new study of more than 3,000 counties in the U.S. finds a correlation between higher levels of particulate air pollution and higher death rates from COVID-19.

Why it matters: COVID-19 may be caused by the novel coronavirus, but the outcome of an infection is influenced by everything from age to race to the environment. Understanding the connection between disease and pollution can help us address those risks going forward.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!